Cargando…

Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study

PURPOSE: The purpose of this study was to assess the potential of (99m)Tc-labeled PSMA-SPECT/CT and diffusion-weighted image (DWI) for predicting treatment response after carbon ion radiotherapy (CIRT) in prostate cancer. PATIENTS AND METHODS: We prospectively registered 26 patients with localized p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Liu, Chang, Wu, Shuang, Deng, Lin, Zhang, Guangyuan, Cai, Xin, Hu, Silong, Cheng, Jingyi, Xu, Xiaoping, Wu, Bin, Guo, Xiaomao, Zhang, Yingjian, Fu, Shen, Zhang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937376/
https://www.ncbi.nlm.nih.gov/pubmed/33688262
http://dx.doi.org/10.2147/CMAR.S285167
_version_ 1783661378606727168
author Li, Ping
Liu, Chang
Wu, Shuang
Deng, Lin
Zhang, Guangyuan
Cai, Xin
Hu, Silong
Cheng, Jingyi
Xu, Xiaoping
Wu, Bin
Guo, Xiaomao
Zhang, Yingjian
Fu, Shen
Zhang, Qing
author_facet Li, Ping
Liu, Chang
Wu, Shuang
Deng, Lin
Zhang, Guangyuan
Cai, Xin
Hu, Silong
Cheng, Jingyi
Xu, Xiaoping
Wu, Bin
Guo, Xiaomao
Zhang, Yingjian
Fu, Shen
Zhang, Qing
author_sort Li, Ping
collection PubMed
description PURPOSE: The purpose of this study was to assess the potential of (99m)Tc-labeled PSMA-SPECT/CT and diffusion-weighted image (DWI) for predicting treatment response after carbon ion radiotherapy (CIRT) in prostate cancer. PATIENTS AND METHODS: We prospectively registered 26 patients with localized prostate cancer treated with CIRT. All patients underwent (99m)Tc-labeled PSMA-SPECT/CT and multiparametric magnetic resonance imaging (MRI) before and after CIRT. The tumor/background ratio (TBR) and mean apparent diffusion coefficient (ADC(mean)) were measured on the tumor and the percentage changes before and after therapy (ΔTBR and ΔADC(mean)) were calculated. Patients were divided into two groups: good response and poor response according to clinical follow-up. RESULTS: The median follow up time was 38.3months. The TBR was significantly decreased (p=0.001), while the ADC(mean) was significantly increased compared with the pretreatment value (p<0.001). The ΔTBR and ΔADC(mean) were negatively correlated with each other (p = 0.002). On ROC curve analysis for predicting treatment response, the area under the ROC curve (AUC) of ΔTBR (0.867) for predicting good response was higher than that of ΔADC(mean) (0.819). The AUC of combined with ΔTBR and ΔADC(mean) (0.895) was higher than that of either ΔADC(mean) or ΔTBR alone. The combined use of ΔTBR and ΔADC(mean) showed 91.4% sensitivity and 95.2% specificity. CONCLUSION: Our preliminary data indicate that the changes of TBR and ADC(mean) maybe an early bio-marker for predicting prognosis after CIRT in localized prostate cancer patients. In addition, the ΔTBR seems to be a more powerful prognostic factor than ΔADC(mean) in prostate cancer treated with CIRT.
format Online
Article
Text
id pubmed-7937376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79373762021-03-08 Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study Li, Ping Liu, Chang Wu, Shuang Deng, Lin Zhang, Guangyuan Cai, Xin Hu, Silong Cheng, Jingyi Xu, Xiaoping Wu, Bin Guo, Xiaomao Zhang, Yingjian Fu, Shen Zhang, Qing Cancer Manag Res Original Research PURPOSE: The purpose of this study was to assess the potential of (99m)Tc-labeled PSMA-SPECT/CT and diffusion-weighted image (DWI) for predicting treatment response after carbon ion radiotherapy (CIRT) in prostate cancer. PATIENTS AND METHODS: We prospectively registered 26 patients with localized prostate cancer treated with CIRT. All patients underwent (99m)Tc-labeled PSMA-SPECT/CT and multiparametric magnetic resonance imaging (MRI) before and after CIRT. The tumor/background ratio (TBR) and mean apparent diffusion coefficient (ADC(mean)) were measured on the tumor and the percentage changes before and after therapy (ΔTBR and ΔADC(mean)) were calculated. Patients were divided into two groups: good response and poor response according to clinical follow-up. RESULTS: The median follow up time was 38.3months. The TBR was significantly decreased (p=0.001), while the ADC(mean) was significantly increased compared with the pretreatment value (p<0.001). The ΔTBR and ΔADC(mean) were negatively correlated with each other (p = 0.002). On ROC curve analysis for predicting treatment response, the area under the ROC curve (AUC) of ΔTBR (0.867) for predicting good response was higher than that of ΔADC(mean) (0.819). The AUC of combined with ΔTBR and ΔADC(mean) (0.895) was higher than that of either ΔADC(mean) or ΔTBR alone. The combined use of ΔTBR and ΔADC(mean) showed 91.4% sensitivity and 95.2% specificity. CONCLUSION: Our preliminary data indicate that the changes of TBR and ADC(mean) maybe an early bio-marker for predicting prognosis after CIRT in localized prostate cancer patients. In addition, the ΔTBR seems to be a more powerful prognostic factor than ΔADC(mean) in prostate cancer treated with CIRT. Dove 2021-03-03 /pmc/articles/PMC7937376/ /pubmed/33688262 http://dx.doi.org/10.2147/CMAR.S285167 Text en © 2021 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Ping
Liu, Chang
Wu, Shuang
Deng, Lin
Zhang, Guangyuan
Cai, Xin
Hu, Silong
Cheng, Jingyi
Xu, Xiaoping
Wu, Bin
Guo, Xiaomao
Zhang, Yingjian
Fu, Shen
Zhang, Qing
Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title_full Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title_fullStr Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title_full_unstemmed Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title_short Combination of (99m)Tc-Labeled PSMA-SPECT/CT and Diffusion-Weighted MRI in the Prediction of Early Response After Carbon Ion Therapy in Prostate Cancer: A Non-Randomized Prospective Pilot Study
title_sort combination of (99m)tc-labeled psma-spect/ct and diffusion-weighted mri in the prediction of early response after carbon ion therapy in prostate cancer: a non-randomized prospective pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937376/
https://www.ncbi.nlm.nih.gov/pubmed/33688262
http://dx.doi.org/10.2147/CMAR.S285167
work_keys_str_mv AT liping combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT liuchang combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT wushuang combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT denglin combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT zhangguangyuan combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT caixin combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT husilong combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT chengjingyi combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT xuxiaoping combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT wubin combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT guoxiaomao combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT zhangyingjian combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT fushen combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy
AT zhangqing combinationof99mtclabeledpsmaspectctanddiffusionweightedmriinthepredictionofearlyresponseaftercarboniontherapyinprostatecanceranonrandomizedprospectivepilotstudy